key: cord-0256345-grylm033
authors: Suzuki, H.; Akashi, Y.; Ueda, A.; Kiyasu, Y.; Takeuchi, Y.; Maehara, Y.; Ochiai, Y.; Okuyama, S.; Notake, S.; Nakamura, K.; Ishikawa, H.
title: Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-CoV-2): a prospective observational study with 1,127 nasopharyngeal samples
date: 2021-07-30
journal: nan
DOI: 10.1101/2021.07.26.21261162
sha: 0d5d997c1574373467d335772b76c32ded59795a
doc_id: 256345
cord_uid: grylm033

Introduction: Digital immunoassays are generally regarded as superior tests for the detection of infectious disease pathogens, but there have been insufficient data concerning SARS-CoV-2 immunoassays. Methods: We prospectively evaluated a novel digital immunoassay (RapidTesta SARS-CoV-2). Two nasopharyngeal samples were simultaneously collected for antigen tests and RT-PCR. Real-time RT-PCR for SARS-CoV-2, using a method developed by the National Institute of Infectious Diseases, Japan, served as the reference RT-PCR method. Results: During the study period, 1,127 nasopharyngeal samples (symptomatic patients: 802, asymptomatic patients: 325) were evaluated. For digital immunoassay antigen tests, the sensitivity was 78.3% (95% CI: 67.3%-87.1%) and the specificity was 97.6% (95% CI: 96.5%-98.5%). When technicians visually analyzed the antigen test results, the sensitivity was 71.6% (95% CI: 59.9%-81.5%) and the specificity was 99.2% (95% CI: 98.5%-99.7%). Among symptomatic patients, the sensitivity was 89.4% (95% CI; 76.9%-96.5%) with digital immunoassay antigen tests, and 85.1% (95% CI; 71.7%-93.8%) with visually analyzed the antigen test, respectively. Conclusions: The findings indicated that RapidTesta SARS-CoV-2 analysis with the DIA device had sufficient analytical performance for the detection of SARS-CoV-2 in nasopharyngeal samples. When positive DIA results are recorded without a visually recognizable red line at the positive line location on the test cassette, additional RT-PCR evaluation should be performed.

COVID-19 has been the primary global health concern for 2 consecutive years (2020 and 2021) and its diagnosis has been mainly performed by respiratory sampling [1] .

RT-PCR has been regarded as the "gold standard" method [1] for the detection of SARS-CoV-2, but a long turnaround time is needed for evaluation of the results.

Immunochromatographic antigen testing is a widely used laboratory technique for the detection of SARS-CoV-2 owing to its ease of handling and rapid acquisition of results [2, 3] ; moreover, a strong correlation between antigen test results and SARS-CoV-2 infectivity has been reported [4] . In recent years, improved sensitivities for pathogen detection using digital immunoassay devices have been proven, especially in the field of influenza [5] , and applications to COVID-19 diagnosis have been expected.

The RapidTesta SARS-CoV-2 is a novel immunochromatographic assay that can detect SARS-CoV-2 in 10 minutes; it was newly approved in Japan in June 2021. The RapidTesta SARS-CoV-2 can be analyzed using a portal digital immunoassay (DIA) device, with presumably greater sensitivity compared with human-eye judgment.

Herein, we performed a prospective comparison with a DIA device and RT-PCR using . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.26.21261162 doi: medRxiv preprint a set of two simultaneously collected nasopharyngeal samples from multiple patients.

The current study was prospectively performed between April 20, 2021, and May 31, 2021, at a "drive-through" PCR center in Tsukuba Medical Center Hospital (TMCH), Tsukuba, Japan. During the study period, patients were mainly referred from 63 clinic and a local public health center. Informed consent was obtained from all participating patients and the study was performed with the approval of the TMCH ethical committee (approval number: 2021-021).

In this study, two nasopharyngeal samples were simultaneously collected with FLOQ Swabs (Copan Italia S.p.A., Brescia, Italy) for RT-PCR and flocked type swabs (contained in the RapidTesta SARS-CoV-2 kit) for antigen tests, as previously described [6] . For antigen tests, each swab was diluted into extraction buffer; three drops of the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.26.21261162 doi: medRxiv preprint extracted sample were then added to a test cassette through filtration ( Figure 1 ). The examination time was 10 minutes; the analysis was performed both visually and automatically with a DIA device ( Figure 2 ). 

Diseases, Japan . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ;

The NIID method has been regarded as the "gold standard" RT-PCR method for SARS-CoV-2 detection and was used as the reference RT-PCR method in this study.

The NIID method was performed with duplicate N and N2 assay analysis, as previous 

The sensitivity, specificity, positive predictive value, and negative predictive value of antigen test results were calculated using the Clopper and Pearson method, with 95% confidence intervals (CIs). All calculations were conducted using R software, version 4.1.0 (www.r-project.org).

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.26.21261162 doi: medRxiv preprint

During the study period, 1,127 nasopharyngeal samples were collected for evaluation.

In total, 802 samples were collected from symptomatic patients and 325 samples were collected from asymptomatic patients.

Of the 1,127 samples, 74 (6.6%) were positive according to RT-PCR with the NIID method. There were no instances of discordance between RT-PCR with the NIID method and in-house RT-PCR; thus, no additional evaluations with the GeneXpert® system were performed.

The results of the RapidTesta SARS-CoV-2 without the use of a DIA device are shown in Table 1 -a. The sensitivity was 71.6% (95% CI: 59.9%-81.5%), and the specificity was 99.2% (95% CI: 98.5%-99.7%). The positive predictive value was 86.9% (95% CI: 75.8%-94.2%), and the negative predictive value was 98.0% (95% CI: 97.0%-98.8%).

The results of the RapidTesta SARS-CoV-2 with the use of a DIA device are shown in Table 1 -b. The sensitivity was 78.4% (95% CI: 67.3%-87.1%), and the specificity was 97.6% (95% CI: 96.5%-98.5%). The positive predictive value was 69.9% (95% CI:

58.8%-79.5%), and the negative predictive value was 98.5% (95% CI: 97.5%-99.1%).

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021.

The results of the RapidTesta SARS-CoV-2 with/without the use of a DIA device are shown in Table 2-a and Table 2 

This prospective study revealed that the sensitivity of the RapidTesta SARS-CoV-2 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; respectively [13]. The sensitivity for positive samples (Ct < 30) was 98.2% (56/57). In our study, the overall sensitivity of the RapidTesta SARS-CoV-2 with a DIA device was comparable with a previous DIA device (QuickChaser Auto SARS-CoV-2). This rapid analysis could be completed within 10 minutes, although its sensitivity for positive samples (Ct < 30) (91.7%; 55/60) was slightly inferior to the previously described DIA device.

False-positive results that indicate the presence of COVID-19 cause substantial harm in clinical practice [14] and the emergence of false-positive results has been repeatedly reported in Japan [15] [16] [17] . In the current study, the increased sensitivity when using the DIA device was negatively associated with the decrease of specificity. There were some limitations to this study. First, study samples were collected in a . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; local district in Japan in the spring of 2021. Second, differences among variant strains were not analyzed. Third, study samples were collected from the nasopharyngeal tract and saliva samples were not analyzed. Fourth, improvements of DIA specificity were not examined and further investigations are necessary.

In conclusion, this study showed that the RapidTesta SARS-CoV-2 with a DIA Mrs. Yoko Ueda and Mrs. Mio Matsumoto substantially contributed to creating the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; database for this study.

Sekisui Medical Co., Ltd. provided fees for research expenses and provided the RapidTesta SARS-CoV-2 without charge. Yuta Maehara, Yasushi Ochiai, and Shinya Okuyama belong to Sekisui Medical Co., Ltd., the developer of the RapidTesta SARS-CoV-2.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. [9] Lee J, Song JU. Diagnostic accuracy of the Cepheid Xpert Xpress and the Abbott ID NOW assay for rapid detection of SARS-CoV-2: a systematic review and meta-analysis. J Med . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; Reverse transcription-polymerase chain reaction findings were used as reference results.

Data in parentheses indicate 95% confidence intervals. Reverse transcription-polymerase chain reaction findings were used as reference results.

Data in parentheses indicate 95% confidence intervals.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. 

World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update

Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection

False positive results in severe acute respiratory coronavirus 2 (SARS-CoV-2) rapid antigen tests for inpatients

False-positive results in SARS-CoV-2 antigen test with rhinovirus-A infection

False-positive for SARS-CoV-2 antigen test in a man with acute HIV infection

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity